Search

An update on inherited retinal disorders (part 1) – overview and assessment of inherited retinal disease

Part 2 of this topic can be found here Inherited Retinal Disease (IRD) is the leading cause of blindness certification in the working age population (age 16-64 years) in England and Wales and the second most common in childhood [1]....

Genetic profiling for personalised healthcare solutions in AMD – an update

Age-related macular degeneration (AMD) is a multifactorial condition influenced by genetics and lifestyle factors (Table 1). This article outlines several recent advances in AMD genetics, as well as evolving therapeutic concepts and established practical measures for the treatment and /...

Neovascular AMD: fresh recommendations underline standards of best practice

The management of neovascular age-related macular degeneration (nAMD) has advanced dramatically over the past seven years, with the introduction of targeted new therapies that successfully maintain or improve vision in a majority of affected individuals. It’s a fast moving field,...

Glaucoma-NET: a novel way of improving glaucoma management in sub-Saharan Africa

Background Glaucoma is the second most common cause of blindness worldwide [1]. People with untreated glaucoma suffer from irreversible, progressive loss of sight. The disease is characterised by progressive loss of visual field, with pathological cupping of the optic disc...

Reflections on a twelve-year partnership: The Makassar-Dundee LINK

In the first article of a two-part series (see Part 2 here), the authors provide an overview of this hugely successful partnership and how they overcame the challenges of COVID-19. What began in 2008 as a connection between equals, has...

6.6.2020 – a celebration of international partnerships

The date 6.6.2020 was selected as a significant milestone for celebrating the achievements of the VISION LINKS Programme as part of the global ‘VISION 2020: The Right to Sight’ initiative [1]. This virtual full-day seminar included LINK partners in the...

Cementing a VISION 2020 LINK partnership between Blantyre and Liverpool – building capacity for DR services alongside research

Malawi is a small land-locked country in eastern Africa with a growing population of over 17 million people. About 45% of the population is aged 14 or under; only 5% are aged 60 or over. The gross national income per...

Gene therapy for inherited retinal disease: the Manchester Ocular Gene Therapy Group MDT service

The authors describe the process set up in Manchester for the optimum delivery and assessment of a new gene therapy treatment for patients with RPE65 IRD. Inherited retinal dystrophies (IRDs) are the second commonest cause of severe visual impairment in...

Patient and public participation shapes biomedical research and access priorities in eye health

Patients, clinicians and clinician-scientists play a valuable role in shaping the future of vision research. Limited funding demands targeted research initiatives that ultimately will shape health policy and practice to secure progress in improving patient outcomes in eye health. This...

The Eye Health Network – an ‘optometry-first’ approach to eye care

Historically, in NHS Grampian, ophthalmology and optometry worked separately, with even the process of optometry referral to hospital occurring only at the behest of the patient’s general practitioner (GP). Criteria for referral were not discussed and feedback after referral was...

Mucormycosis: In conversation with Dr Deepak Haldipur and Dr Aditya Moorthy

COVID-19 has ravaged the world in the past 18 months. The second wave in many countries was deadlier than the first. Mucormycosis, infamously labelled ‘the black fungus’ has affected some countries, such as India, in epidemic proportions within this COVID...